Functional imaging of tumours with 99Tcm-sestamibi pinhole scintigraphy

Nuclear Medicine Communications

Volumn 17, Issue 11, 1996, Pages 943-951

  Koukouraki, S ^a   Androulakis, E ^a   Karkavitsas, N ^a   Damilakis, J ^a   Koukourakis, M ^a   Giatromanolaki, A ^b  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; TREATMENT OUTCOME;

EID: 0029826269     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199611000-00004     Document Type: Article

References (29)

1. Holman, BL, Jones AG, Lister-James J et al. A new Tc-99m-labeled myocardial imaging agent, hexakis (t-butylisoni-trile) technetium (I)[Tc-99m TBI]: Initial experience in the human. J Nucl Med 1984; 25: 1350-1355.
2. Mueller S, Guth-Tougelides B, Creutzig H. Imaging of malignant tumours with 99mTc-sestamibi. J Nucl Med 1987; 28: 562.
3. Hassan IM, Sahweil A, Constantinides C et al. Uptake and kinetics of 99m-Tc-MIBI in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14: 333-340.
4. Caner B, Kitapci M, Aras T. 99m-Tc-MIBI uptake in benign and malignant bone lesions: A comparative study with 99m-Tc-MDP. J Nucl Med 1992; 33: 319-324.
5. Burak Z, Argon M, Memis A et al. Evaluation of palpable breast masses with 99m-Tc-MIBI: A comparative study with mammography and ultrasonography. Nucl Med Commun 1994; 15: 604-612.
6. Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: A new role of prone scintimammography using 99m Tc-Sesta-Mibi. Eur J Nucl Med 1994; 21: 357-362.
7. Nagaraj N, Waxman A, Ashock S et al. Comparison of SPET and planar Tc-99m-sestamibi imaging in patients with carcinoma of the breast (abstract). J Nucl Med 1994; 35: 229.
8. Scopinaro F, Schillaci O, Scarpini M et al. Technetium-99m: An indicator of breast cancer invasiveness. Eur j Nucl Med 1994; 21: 984-987.
9. O Tuama LA, Treves ST, Larar JN et al. Thallium 201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumours: A within-subject comparison. J Nucl Med 1993; 34: 1045-1051.
10. Kao CH, Wang SJ, Lin WY, Hsu CY, Liao SQ, Yeh SH. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m-methoxyisonitrile. Eur J Nucl Med 1993; 20: 249-254.
11. Nemec J, Nyvitova O, Vlcek P et al. Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisoni-trile. Eur J Nucl Med 1996; 23: 69-71.
12. Rao VV, Chiu ML, Krounage JF, Worms PD. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium sestamibi. J Nucl Med 1994; 35: 510-515.
13. Meerdink D, Leppo JA. Comparison of hypoxia and qua-bain effects on the myocardial uptake kinetics of techne-tium-99m-hexakis 2-methoxyisobutyl isonitrile and thallium-201. J Nucl Med 1989; 30: 1500-1506.
14. Giatromanolaki A, Koukourakis M, O’Byrne K et al. Angio-genesis is a significant prognostic marker in operable non small cell lung cancer. J Pathol (in press).
15. Horak ER, Leek R, Klenk N et al. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124.
16. Koukourakis M, Damilakis J. LQ-based model for biological radiotherapy planning. Med Dosim 1994; 19: 269-277.
17. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buoncore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[(18)F]deoxyglucose (2-[(19)FFDG]). Gynecol Oncol 1993; 51: 197-204.
18. Maublant JC, Zhang Z, Rapp M, Oilier M, Michelot J, Veyre A. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: Comparison with techne-tium-99m-sestamibi and thallium-201. J Nucl Med 1993; 34: 1949-1952.
19. Carvalho PA, Ciu ML, Kronauge JF et al. Subcellular distribution and analysis of 99mTc-sestamibi in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1521.
20. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis Tc in cultured mouse fibroblast. J Nucl Med 1990; 31: 1646-1653.
21. Piwnica-Worms D, Chiu ML, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
22. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI. Reversal of multidrug resistance to cancer chemotherapy. Cancer 1993; 72: 3484-3488.
23. Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL, Carmichael J. Selective reversal of vinblastin resistance in multidrug resistant cell lines by tamoxifen, toremifen and their metabolites. Eur j Cancer 1993; 29: 1152-1157.
24. Fontanini G, Birgini F, Vignati S et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995; 177: 57-63.
25. Denekamp J. Does physiological hypoxia matter in cancer therapy? In: Steel GG, Adams GE, Peckham MJ, eds. The biological basis of radiotherapy. Amsterdam: Elsevier, 1983: 139-155.
26. Dische S. Hypoxia and local tumour control. Part 2. Radio-titer Oncol 1991; 20(suppl.): 9-11.
27. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Giatromanolaki A, Yannakakis D. The impact of overall treatment time on the results of radiotherapy for non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys (in press).
28. Hendry JH. Treatment acceleration in radiotherapy: The relative time factors and dose-response slopes for tumours and normal tissues. Radiother Oncol 1992; 25: 308-312.
29. Mountain CF. Chest 1986; 89(suppl.): 225-233.